NCT01666756View on ClinicalTrials.gov

Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 11, 2014

Primary Completion Date

May 29, 2020

Study Completion Date

May 29, 2020

Conditions
Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerAdvanced Adult Hepatocellular CarcinomaBCLC Stage B Adult Hepatocellular CarcinomaBCLC Stage C Adult Hepatocellular Carcinoma
Interventions
DIETARY_SUPPLEMENT

Chinese herbal formulation PHY906

Given PO

DRUG

sorafenib tosylate

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT01666756 - Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | Biotech Hunter | Biotech Hunter